Survival of Patients with Primary Brain Tumor: A Data Analysis of 10 Years


Citar

Texto integral

Resumo

Background::The prognosis for primary brain tumors, like other CNS tumors, can vary greatly based on several factors, such as treatment history, age and gender at diagnosis, ethnic background, and treatment plan.

Materials and Method::A systematic review approach was used to gather relevant data from PubMed, ScienceDirect, Google Scholar, and other sources.

Results::The survival rate of primary brain tumors and other CNS tumors appears to be correlated with several variables, including treatment history, gender, age at evaluation, race/ethnicity, and treatment regimen; this emphasizes the importance of routinely updating epidemiological data on primary brain tumors to advance biological understanding.

Conclusion::This study draws attention to the variations in the median survival times of the various kinds of primary brain tumors, with oligodendroglioma having the longest median survival time (199 months, or approximately 16.6 years) and glioblastoma having the shortest (8 months).

Sobre autores

Shristy Verma

Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University

Email: info@benthamscience.net

Rishabha Malviya

Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University

Autor responsável pela correspondência
Email: info@benthamscience.net

Prerna Uniyal

School of Pharmacy, Graphic Era Hill University

Email: info@benthamscience.net

Bibliografia

  1. Kruchko C, Ostrom QT, Gittleman H, Barnholtz-Sloan JS. The CBTRUS story: Providing accurate population-based statistics on brain and other central nervous system tumors for everyone. Neuro-oncol 2018; 20(3): 295-8. doi: 10.1093/neuonc/noy006 PMID: 29471448
  2. Low JT, Ostrom QT, Cioffi G, et al. Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians. Neurooncol Pract 2022; 9(3): 165-82. doi: 10.1093/nop/npac015 PMID: 35601966
  3. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro-oncol 2021; 23(12): 31-315. doi: 10.1093/neuonc/noab200 PMID: 34608945
  4. Epidemiology S, Results E. Surveillance epidemiology and end results (SEER) program. Cancer incidence rates adjusted for reporting delay. 2020. Available from: http://surveillance.cancer.gov/delay/ (Accessed January 17 2024).
  5. Kruchko C, Gittleman H, Ruhl J, et al. Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors. Neurooncol Pract 2019; 6(5): 330-9. doi: 10.1093/nop/npz029 PMID: 31555447
  6. Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro-oncol 2022; 24: v1-v95. doi: 10.1093/neuonc/noac202 PMID: 36196752
  7. Islami F, Ward EM, Sung H, et al. Annual report to the nation on the status of cancer, part 1: National Cancer Statistics. J Natl Cancer Inst 2021; 113(12): 1648-69. doi: 10.1093/jnci/djab131 PMID: 34240195
  8. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391(10125): 1023-75. doi: 10.1016/S0140-6736(17)33326-3 PMID: 29395269
  9. Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci 2018; 54: 7-13. doi: 10.1016/j.jocn.2018.05.002 PMID: 29801989
  10. Senders JT, Staples P, Mehrtash A, et al. An online calculator for the prediction of survival in glioblastoma patients using classical statistics and machine learning. Neurosurgery 2020; 86(2): E184-92. doi: 10.1093/neuros/nyz403 PMID: 31586211
  11. Kang MJ, Won YJ, Lee JJ, et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2019. Cancer Res Treat 2022; 54(2): 330-44. doi: 10.4143/crt.2022.128 PMID: 35313102
  12. Girardi F, Di Carlo V, Stiller C, et al. Global survival trends for brain tumors, by histology: Analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3). Neuro-oncol 2023; 25(3): 593-606. doi: 10.1093/neuonc/noac232 PMID: 36215122
  13. Woo PYM, Yau S, Lam TC, et al. Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: A Hong Kong population level analysis over a 14-year period. Neurooncol Pract 2023; 10(1): 50-61. doi: 10.1093/nop/npac069 PMID: 36659973

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2024